EU Approves First Drug for Cerebral ALD

The European Commission granted marketing authorization on 21 September 2026 to Nezglyal (leriglitazone), making it the first pharmacological treatment approved anywhere for cerebral adrenoleukodystrophy (cALD) — a rare, aggressive, childhood-onset neurodegenerative disease that until now has had no drug option at all, only stem cell transplantation for eligible patients caught early enough. The authorization, developed by Spain's Minoryx Therapeutics and commercialized in Europe by Neuraxpharm, is deliberately narrow: it covers boys aged 2 to 12 with early-stage disease, and it follows a clinical program in which the companion adult trial did not hit its own primary endpoint.

What cerebral ALD is, and why the treatment window is so narrow

Adrenoleukodystrophy is a rare, X-linked genetic disorder of very-long-chain fatty acid metabolism. Its cerebral form strikes boys, typically between ages 4 and 12, and can progress from an early MRI finding to severe neurological disability within months once active brain inflammation sets in. The only established intervention, hematopoietic stem cell transplantation, only works if it is performed early, before Gadolinium-enhancing lesions signal that active, progressive brain demyelination has begun — which is precisely the population this approval targets. Leriglitazone is a PPAR-gamma agonist, taken orally once daily, intended to be started even earlier, in Gd-negative boys whose disease has not yet reached that active inflammatory stage, with a Neurological Functional Score of 0 or 1 meaning minimal to no measurable neurological impairment yet.

A first-in-disease approval built on an endpoint that missed

The clinical program behind Nezglyal runs across two trials. NEXUS, an open-label Phase 2/3 study, enrolled children with cALD directly and is the trial most closely tied to today's pediatric indication. ADVANCE, a randomized, double-blind, placebo-controlled Phase 2/3 trial, tested leriglitazone in adult men with adrenomyeloneuropathy — a related but distinct, slower-progressing form of ALD affecting the spinal cord and peripheral nerves rather than the brain — and its primary endpoint was not met. That result does not directly undercut the pediatric cALD approval, which rests on the separate NEXUS data and a narrower population, but it is exactly the kind of program history that belongs in any honest account of this approval: a genuine unmet-need, first-in-disease authorization, granted on a mixed evidence record, with a deliberately narrow label to match what the evidence actually supports.

What the companies are saying

“cALD is a severe neurodegenerative disease and we look forward to bringing Nezglyal, a long-awaited treatment, to European patients following EC approval,” said Jörg Thomas Dierks, chief executive of Neuraxpharm, per the companies' joint statement. Minoryx chief executive Marc Martinell has previously described leriglitazone, ahead of today's authorization, as potentially “the only pharmacological treatment for patients suffering from this devastating orphan disease” — a claim this approval now makes literally true, for the specific Gd-negative pediatric population the label covers.

What happens next

• National reimbursement: EU marketing authorization is EU-wide, but pricing and reimbursement decisions are made country by country — the practical availability timeline will vary by member state.
• Screening implications: because the label depends on catching disease before Gadolinium-enhancing lesions appear, this approval raises the stakes on newborn and at-risk-family ALD screening and MRI surveillance programs across the EU.
• Watch for adult-population data: ADVANCE's missed primary endpoint does not close the door on adrenomyeloneuropathy as a future indication, but any expansion there would need a stronger efficacy case than this trial delivered.

Frequently asked questions

What did the European Commission approve on 21 September 2026?

Marketing authorization for Nezglyal (leriglitazone) for cerebral adrenoleukodystrophy in boys aged 2 to 12 with Gd-negative brain lesions and a Neurological Functional Score of 0 or 1 — the first pharmacological treatment authorized for cALD in the EU.

What clinical evidence supports the approval?

The pediatric NEXUS trial plus the adult ADVANCE trial in the related condition adrenomyeloneuropathy, whose primary endpoint was not met; the pediatric cALD label is narrowly scoped to the population NEXUS and the wider program best support.

How does this fit with the CHMP process?

CHMP adopted a positive opinion in July 2026; the European Commission's binding marketing authorization followed on 21 September 2026.

Is this the same disease as adult adrenomyeloneuropathy?

No — both are forms of ALD, but cerebral ALD is the aggressive, childhood-onset brain form this approval targets, while adrenomyeloneuropathy is a distinct, slower, typically adult-onset spinal cord and nerve condition, the one studied in the ADVANCE trial that missed its endpoint.